Myeloid targeting antibody - Agenus
Latest Information Update: 28 Jan 2022
Price :
$50 *
At a glance
- Originator Agenus
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Immunological disorders
Most Recent Events
- 18 Jan 2022 Myeloid targeting antibody - Agenus is available for licensing as of 18 Jan 2022. https://agenusbio.com/about/contact/
- 18 Jan 2022 Preclinical trials in Cancer in USA (Parenteral), before January 2022 (Agenus pipeline, January 2022)
- 18 Jan 2022 Preclinical trials in Immunological disorders in USA (Parenteral), before January 2022 (Agenus pipeline, January 2022)